• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 9th March 2022

No Smoking Day 2022: Reflecting on OHE Projections from 1994

Since 1984, the UK’s second Wednesday of each March is NO SMOKING DAY (NSD). The NSD aims to encourage smokers who want to quit. In 2022, NSD falls on the 9th of March and has the slogan “Today is the…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
No-Smoking-Day-graph-smaller

Since 1984, the UK’s second Wednesday of each March is NO SMOKING DAY (NSD). The NSD aims to encourage smokers who want to quit. In 2022, NSD falls on the 9th of March and has the slogan “Today is the Day”.

On the occasion of the 2022 NSD, a reflection on where the UK is regarding smoking trends is warranted. A historical OHE publication (1) adds an interesting perspective. It allows us to ponder whether deaths and cases associated with lung cancer, mainly due to smoking, are where we expected them to be back in 1994.

In 2019, about 1.14 billion individuals worldwide were active smokers, and smoking tobacco accounted for approximately 7.69 million deaths and 200 million disability-adjusted life-years. Smoking tobacco was the leading risk factor for death among males, accounting for 20.2% of deaths (2).

Cigarette smoking explains above 80% of lung cancer deaths (5), and, interestingly, OHE, in 1994, published a study that predicted a significant increase in the number of cases and deaths from lung cancer from 1985 to 2017 based on a simple extrapolation (standard forecast) of 1985 data by the Office of Population Statistics Survey. This prediction relied on the British population growing from 57.8 million to 61.7 million in twenty-five years. Additionally, an adjusted forecast was elicited from a UK expert panel. The standard- and expert-based predicted figures for lung cancer deaths for 2017 in the UK were 69,700 and 57,900, and, for cases, 51,200 and 41,200. Hence, the expert panel shifted the standard forecast downwards by about 17% for deaths and 19% for cases.

Retrospective data gathered by the Global Disease Burden Study (3) shows that the actual number of deaths due to lung cancer in the UK in 2017 was about 49,390, well below the standard and the expert-based predictions. Interestingly, the number of new cases in 2017 was 79,863, which is above the predictions of the expert panel and quite close to the standard prediction. In the meantime, the British population grew by almost four million more than predicted, reaching 65.6 million in 2017.

Source: OHE analysis using CRUK (6) and ONS (7) data. SP: Standard projection. EF: Expert Forecast

Comparing the predictions in OHE (1) and reality spawns several considerations. Firstly, the fact that the actual number of deaths is lower than the standard projection, despite the much larger actual increase in the population (as assumed by the projection), signals that medical treatment for lung cancer has advanced even more than predicted by the experts.

Secondly, the actual prevalence is higher than both forecasts due to the population growth, despite a decrease in the uptake of smoking in the UK (9).

The findings above corroborate the amply documented (3,4) effectiveness of demand-reduction policies in lowering the incidence and prevalence of smoking tobacco even in countries with very diverse income levels. Demand-reduction policies in use since 1990 have ranged from banning cigarette advertisements to cigarette packs containing health warnings, increasing tobacco products excise taxes, and outlawing smoking in public transport and public and private spaces. However, there are still reasons to limit our optimism. Countries with large populations and high prevalence are still experiencing increased deaths attributable to tobacco smoking (i.e., China, Indonesia). Second, nations with intense population growth experience constant or increasing smokers over time (2). These two factors combined explain the still massive burden of disease of smoking tobacco in the world.

Bringing back the focus of the original 1994 OHE briefing, behavioural changes imposed by anti-smoking demand-side interventions worldwide and medical advancement in the detection and treatment of cancer have contributed markedly to ameliorating the burden on smoking on society. However, there is still a way to go.

References

  1. Hall, M. (1994) The Impact of Behavioural and Biomedical Advance on Health Trends over the Next 25 Years. OHE Briefing.
  2. Reitsma, M. B. et al. (2019) Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. The Lancet, Volume 397, Issue 10292, 2337 – 2360
  3. Data from Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD, 2019) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2020. Available from http://ghdx.healthdata.org/gbd-results-tool.
  4. Henriksen L (2012) Comprehensive tobacco marketing restrictions: promotion, packaging, price and place. Tobacco Control, 21:147-153.
  5. Walser T, Cui X, Yanagawa J, et al. Smoking and lung cancer: the role of inflammation. Proc Am Thorac Soc. 2008;5(8):811-815. doi:10.1513/pats.200809-100TH
  6. Mansournia M A, Altman D G. Population attributable fraction BMJ 2018; 360 :k757 doi:10.1136/bmj.k757
  7. Cancer Research UK, https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/mortality#heading-Two
  8. Office for National Statistics  http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarria
  9. Office for National Statistics Smoking prevalence in the UK and the impact of data collection changes – Office for National Statistics (ons.gov.uk)

Citation

Hall, M. (1994) The Impact of Behavioural and Biomedical Advance on Health Trends over the Next 25 Years. OHE Briefing.

 

  • Healthcare Systems
  • Value, Affordability, and…
  • Briefing

Related Insights

Key-Learnings-small
  • Insight
  • April 2021

Key Learnings From COVID-19: The Importance of Portfolio Management and How to Procure, Pay For, Distribute, and Use Vaccines During a Pandemic

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!